Black DR, Minkin MJ, Graham S, et al. - Researchers aimed at determining how a single-capsule 17β-estradiol (E2)/progesterone (P4) affects weight and blood pressure (BP) when treating moderate to severe vasomotor symptoms in postmenopausal women with a uterus. The phase 3 REPLENISH trial was performed including healthy postmenopausal women with a uterus (aged 40-65, body mass index ≤ 34 kg/m², BP ≤140/90 mm Hg) and randomizing them to daily E2/P4 (mg/mg; 1/100, 0.5/100, 0.5/50, 0.25/50) or placebo. Overall, there were modest and generally not statistically or clinically significant mean changes in weight and BP from baseline to month 12 in correlation with E2/P4 vs placebo. This suggests that 12-month use of E2/P4 is not linked with any clinically meaningful impact on weight or BP in postmenopausal women of the REPLENISH study.